Odyssey Therapeutics, Inc. (ODTX) fair value analysis
Nasdaq · Updated 2026-10-19
ODTX price how computed
Valuation status
No fair-value estimate yetODTX has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ODTX yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $17.17
- Sector
- Healthcare
- 12-month range
- $16.42–$24.50
- Market cap
- $825M
- From 52-week high
- -29.9%
- Shares outstanding
- 48.1M
- Rank in Healthcare by quality score
- #258 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Odyssey Therapeutics, Inc. is a biopharmaceutical company that develops therapies focused on rare genetic diseases and oncology. The company is based in the United States and operates as a publicly traded entity on the Nasdaq exchange.
ODTX currently ranks #258 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $825M
- Revenue (TTM)
- $2.88M
- Net margin
- -5934.0%
- Debt / equity
- 0.06
- Shares outstanding
- 48.1M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 34 · neutral
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 2 quarters vs consensus
- 0 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-51.8%)
2026-03 ▼ miss (-427.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 0 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $35.3
- Target vs last price
- +105.6%
What our data shows for ODTX
- Shares are trading in the lower third of their 12-month price range of $16.42–$24.50.
- The 14-day relative strength index sits at a neutral 34.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ODTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ODTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ODTX stock undervalued?
TickrTrends has no fair-value estimate for ODTX yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ODTX's TickrTrends verdict?
ODTX is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ODTX compare to other Healthcare stocks?
ODTX ranks #258 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ODTX overbought or oversold?
ODTX's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does ODTX report earnings next?
ODTX's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does ODTX usually beat earnings estimates?
Over its last 2 reported quarters ODTX beat the consensus estimate 0 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ODTX?
Of 6 analysts covering ODTX, 6 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $35.3 (+105.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.